Perrigo Plc(NYSE) PRGO

Perrigo makes everyday health products like allergy medicine and infant formula. It helps families treat common conditions without a doctor's prescription. The company focuses on making wellness options affordable and accessible.

What Perrigo Puts in the Cabinet

• Upper Respiratory: Products that relieve cough, sinus, and allergy symptoms for consumers.
• Nutrition: Infant formulas and electrolyte beverages sold primarily in the United States and Canada.
• Digestive Health: Non-prescription treatments for heartburn, indigestion, and other stomach-related issues.
• Pain and Sleep-Aids: Medicine used to reduce fever, manage pain, and assist with sleep.
• Women's Health: Essential wellness and contraceptive products, including the Opill daily birth control brand.

Building a Faster Supply Chain

• Finalized the Supply Chain Reinvention Program in 2025 to lower costs and improve service levels.
• Divested the HRA Rare Diseases Business in 2024 to simplify the global product portfolio.
• Launched Project Energize as a global investment program to drive efficiency and sustainable results.
• Proposed the sale of the Dermacosmetics branded business to focus on core self-care categories.
• Transitioned to a category-based reporting structure in early 2026 to better align with strategic priorities.

How Perrigo Stays Competitive

Perrigo uses a strategy called the Three-S plan to stabilize its formula business and streamline global operations. It manages a massive supply chain that delivers hundreds of different medicine ingredients at multiple price points. This scale allows the company to reach more households than many specialized competitors.

The Latest Financial Numbers

• Net sales reached $1.1 billion in Q4 2025, down 2.5% from the same period last year.
• Operating income was $84.7 million in Q4 2025, representing a 25.8% decrease year-over-year.
• Net income dropped to -$1.4 billion in Q4 2025, as the loss deepened from -$44.5 million in Q4 2024.
• Free cash flow hit $148.6 million in Q4 2025, a 45.9% decline from the previous year.
• Sales to Walmart Inc. accounted for 12.9% of total consolidated net sales during 2025.

Bottom Line

Perrigo has successfully transitioned from a broad pharmaceutical manufacturer into a focused consumer self-care company. By selling off its prescription and rare disease units, it is now prioritizing high-growth wellness brands and affordable store-brand alternatives.